Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). Both VEGFR and EGFR pathways have emerged as instrumental in the growth and metastasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Flanigan, Jaclyn, Deshpande, Hari, Gettinger, Scott
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943196/
https://www.ncbi.nlm.nih.gov/pubmed/20859451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943196/
https://www.ncbi.nlm.nih.gov/pubmed/20859451

Ejemplares similares